Bayer (BAYRY) and Attralus announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 and AT-05, two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from Attralus. The acquired molecular imaging portfolio consists of AT-01 in Phase III of clinical development and AT-05 in Phase I of clinical development, focused on the diagnosis of cardiac amyloidosis. The financial details of the acquisition were not disclosed.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis
- Bayer’s FINE-REAL Korea Study Tracks Real-World Use of Finerenone in Diabetic Kidney Disease
- Bayer’s New Parkinson’s Study Builds a Long-Term Data Edge, Not Near-Term Profits
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy
- Bayer’s BAY3018250 DVT Study Reaches Completion: What It Means for Investors